Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This randomized double-blind, placebo-controlled phase 2 trial is evaluating superiority of
Letrozole-palbociclib combination versus letrozole-placebo combination in ER positive
endometrioid adenocarcinoma of endometrium
Phase:
Phase 2
Details
Lead Sponsor:
Nordic Society for Gynaecologic Oncology Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Collaborators:
ENGOT European Network of Gynaecological Oncological Trial Groups (ENGOT) GCIG Grupo Español de Investigación en Cáncer de Ovario Gynecologic Cancer Intergroup (GCIG) Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) North Eastern German Society of Gynaecological Oncology